New drug cocktail aims to shrink triple-positive breast tumors before surgery
NCT ID NCT07299890
First seen Jan 05, 2026 · Last updated May 13, 2026 · Updated 20 times
Summary
This study tests a combination of four drugs (trastuzumab, pertuzumab, palbociclib, and exemestane) given before surgery to people with early or locally advanced triple-positive breast cancer. The goal is to see if this treatment can eliminate all signs of cancer in the breast and lymph nodes at the time of surgery. About 90 participants will receive the drug combination, and researchers will monitor how well it works and what side effects occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.